Trial watch: Oncolytic viruses for cancer therapy

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Pol, Jonathan ^a,b,c,d   Bloy, Norma ^a,b,c,d   Obrist, Florine ^a,b,c,d   Eggermont, Alexander ^a   Galon, Jérôme ^c,e,f,g   Cremer, Isabelle ^c,e,f,g   Erbs, Philippe ^h   Limacher, Jean Marc ^h   Preville, Xavier ^h   Zitvogel, Laurence ^a,g   Kroemer, Guido ^b,c,e,i,j   Galluzzi, Lorenzo ^a,c,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Institut Gustave Roussy   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSERM   (France)

^h TRANSGENE S A   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j Metabolomics Platform   (France)

more..

Author keywords

Adenovirus; ColoAd1; Mesenchymal stem cells; MV NIS; Reolysin; Talimogene laherparepvec

Indexed keywords

CG 0070; CGTG 102; COLOAD1; COXSACKIEVIRUS A21; DEXAMETHASONE; DNX 2401; FLUCYTOSINE; HSV 1716; ICOVIR 5; MV NIS; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VCN 01; VOCIMAGENE AMIRETROREPVEC;

BLADDER CARCINOMA; BRAIN TUMOR; CANCER CELL; CANCER PATIENT; CANCER RESEARCH; CANCER SURGERY; CELL DEATH; COLORECTAL CARCINOMA; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84906483079     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28694     Document Type: Review

References (287)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
2. Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 2001; 93:998-1007; PMID:11438565; http://dx.doi.org/10.1093/jnci/93.13.998
3. Mäkelä AR, Matilainen H, White DJ, Ruoslahti E, Oker-Blom C. Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J Virol 2006; 80:6603-11; PMID:16775347; http://dx.doi.org/10.1128/JVI.00528-06
4. Singh P, Destito G, Schneemann A, Manchester M. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology 2006; 4:2; PMID:16476163; http://dx.doi.org/10.1186/1477-3155-4-2
5. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216; PMID:17383089; http://dx.doi.org/10.1016/j.canlet.2007.02.002
6. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. Viral control of mitochondrial apoptosis. PLoS Pathog 2008; 4:e1000018; PMID:18516228; http://dx.doi.org/10.1371/journal.ppat.1000018
7. Boisgerault N, Guillerme JB, Pouliquen D, Mesel-Lemoine M, Achard C, Combredet C, Fonteneau JF, Tangy F, Grégoire M. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Res Int 2013; 2013:387362; PMID:23586034; http://dx.doi.org/10.1155/2013/387362
8. Stanford MM, Bell JC, Vähä-Koskela MJ. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2010; 21:177-83; PMID:20219409; http://dx.doi.org/10.1016/j.cytogfr.2010.02.012
9. Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, Smerdou C. Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology 2012; 1:1344-54; PMID:23243597; http://dx.doi.org/10.4161/onci.21679
10. Hemminki A, Oksanen M, Merisalo-Soikkeli M. Oncolytic virotherapy trials--letter. Clin Cancer Res 2013; 19:4541-2; PMID:23946419; http://dx.doi.org/10.1158/1078-0432.CCR-13-1471
11. Walther W, Schlag PM. Current status of gene therapy for cancer. Curr Opin Oncol 2013; 25:659-64; PMID:24100345; http://dx.doi.org/10.1097/CCO.0000000000000004
12. Donnelly O, Harrington K, Melcher A, Pandha H. Live viruses to treat cancer. J R Soc Med 2013; 106:310-4; PMID:23824333; http://dx.doi.org/10.1177/0141076813494196
13. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012; 23:484-91; PMID:22171635; http://dx.doi.org/10.1089/hum.2011.146
14. Muik A, Kneiske I, Werbizki M, Wilflingseder D, Giroglou T, Ebert O, Kraft A, Dietrich U, Zimmer G, Momma S, et al. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 2011; 85:5679-84; PMID:21450833; http://dx.doi.org/10.1128/JVI.02511-10
15. Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther 2013; 21:561-9; PMID:23070115; http://dx.doi.org/10.1038/mt.2012.211
16. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 2013; 73:865-74; PMID:23293278; http://dx.doi.org/10.1158/0008-5472.CAN-12-2221
17. Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, et al. Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog 2013; 9:e1003155; PMID:23382683; http://dx.doi.org/10.1371/journal.ppat.1003155
18. Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010; 70:3890-5; PMID:20424118; http://dx.doi.org/10.1158/0008-5472.CAN-10-0155
19. Lee CY, Bu LX, DeBenedetti A, Williams BJ, Rennie PS, Jia WW. Transcriptional and translational dualregulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther 2010; 18:929-35; PMID:20179676; http://dx.doi.org/10.1038/mt.2010.26
20. Cuevas Y, Hernández-Alcoceba R, Aragones J, Naranjo-Suárez S, Castellanos MC, Esteban MA, Martín-Puig S, Landazuri MO, del Peso L. Specific oncolytic effect of a new hypoxia-inducible factordependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 2003; 63:6877-84; PMID:14583486
21. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22:2065-72; PMID:12687009; http://dx.doi.org/10.1038/sj.onc.1206464
22. Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, Chang SS, Chen PJ. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int J Cancer 2013; 132:1451-62; PMID:22886913; http://dx.doi.org/10.1002/ijc.27770
23. Takahashi H, Hyakusoku H, Horii C, Takahashi M, Nishimura G, Taguchi T, Kondo N, Sakakibara A, Urata Y, Sano D. Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells. Head Neck 2014; 36:411-8; PMID:23728900; http://dx.doi.org/10.1002/hed.23309
24. Jin C, Yu D, Čančer M, Nilsson B, Leja J, Essand M. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy. Hum Gene Ther 2013; 24:766-75; PMID:23889332; http://dx.doi.org/10.1089/hum.2012.132
25. Wang W, Ji W, Hu H, Ma J, Li X, Mei W, et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy. Oncotarget 2013.
26. Sugio K, Sakurai F, Katayama K, Tashiro K, Matsui H, Kawabata K, Kawase A, Iwaki M, Hayakawa T, Fujiwara T, et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011; 17:2807-18; PMID:21346145; http://dx.doi.org/10.1158/1078-0432.CCR-10-2008
27. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 2010; 84:1550-62; PMID:19906911; http://dx.doi.org/10.1128/JVI.01788-09
28. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumorspecific replication. Mol Ther 2008; 16:1437-43; PMID:18560417; http://dx.doi.org/10.1038/mt.2008.130
29. Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 2008; 14:1278-83; PMID:18953352; http://dx.doi.org/10.1038/nm.1776
30. Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, et al. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One 2013; 8:e73964; PMID:24069256; http://dx.doi.org/10.1371/journal.pone.0073964
31. Li JM, Kao KC, Li LF, Yang TM, Wu CP, Horng YM, Jia WW, Yang CT. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol J 2013; 10:241; PMID:23876001; http://dx.doi.org/10.1186/1743-422X-10-241
32. Ylösmäki E, Lavilla-Alonso S, Jäämaa S, Vähä-Koskela M, af Hällström T, Hemminki A, Arola J, Mäkisalo H, Saksela K. MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver. PLoS One 2013; 8:e54506; PMID:23349911; http://dx.doi.org/10.1371/journal.pone.0054506
33. Yang X, Chen E, Jiang H, Muszynski K, Harris RD, Giardina SL, Gromeier M, Mitra G, Soman G. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J Virol Methods 2009; 155:44-54; PMID:18951922; http://dx.doi.org/10.1016/j.jviromet.2008.09.020
34. Ammayappan A, Nace R, Peng KW, Russell SJ. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol 2013; 87:3217-28; PMID:23283963; http://dx.doi.org/10.1128/JVI.02984-12
35. Goetz C, Gromeier M. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 2010; 21:197-203; PMID:20299272; http://dx.doi.org/10.1016/j.cytogfr.2010.02.005
36. Banaszynski LA, Sellmyer MA, Contag CH, Wandless TJ, Thorne SH. Chemical control of protein stability and function in living mice. Nat Med 2008; 14:1123-7; PMID:18836461; http://dx.doi.org/10.1038/nm.1754
37. Glass M, Busche A, Wagner K, Messerle M, Borst EM. Conditional and reversible disruption of essential herpesvirus proteins. Nat Methods 2009; 6:577-9; PMID:19578384; http://dx.doi.org/10.1038/nmeth.1346
38. Li J, Liu H, Li L, Wu H, Wang C, Yan Z, Wang Y, Su C, Jin H, Zhou F, et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol Rep 2013; 29:895-902; PMID:23292657
39. Shobana R, Samal SK, Elankumaran S. Prostatespecific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol 2013; 87:3792-800; PMID:23345509; http://dx.doi.org/10.1128/JVI.02394-12
40. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4:263-75; PMID:14585354; http://dx.doi.org/10.1016/S1535-6108(03)00241-1
41. Sarinella F, Calistri A, Sette P, Palù G, Parolin C. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Rasactivation, but on the PI 3-kinase pathway. Gene Ther 2006; 13:1080-7; PMID:16554839; http://dx.doi.org/10.1038/sj.gt.3302770
42. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80:5145-55; PMID:16698995; http://dx.doi.org/10.1128/JVI.02618-05
43. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6:821-5; PMID:10888934; http://dx.doi.org/10.1038/77558
44. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-4; PMID:9812900; http://dx.doi.org/10.1126/science.282.5392.1332
45. Cheng PH, Rao XM, McMasters KM, Zhou HS. Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirusinduced cyclin E. PLoS One 2013; 8:e57340; PMID:23437375; http://dx.doi.org/10.1371/journal.pone.0057340
46. Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA. STAT3 activation promotes oncolytic HSV1 replication in glioma cells. PLoS One 2013; 8:e71932; PMID:23936533; http://dx.doi.org/10.1371/journal.pone.0071932
47. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6:529-40; PMID:18552863; http://dx.doi.org/10.1038/nrmicro1927
48. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59:410-3; PMID:9927055
49. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 2006; 47:1136-43; PMID:16818948
50. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM, Erbs P. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15:1361-71; PMID:18480846; http://dx.doi.org/10.1038/gt.2008.82
51. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006; 13:845-55; PMID:16710344; http://dx.doi.org/10.1038/sj.cgt.7700962
52. Leveille S, Samuel S, Goulet ML, Hiscott J. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 2011; 18:435-43; PMID:21394109; http://dx.doi.org/10.1038/cgt.2011.14
53. Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A, Karlsson A, Xu K, Zheng X. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. Cancer Lett 2013; 328:95-103; PMID:23000515; http://dx.doi.org/10.1016/j.canlet.2012.09.003
54. Hartkopf AD, Bossow S, Lampe J, Zimmermann M, Taran FA, Wallwiener D, Fehm T, Bitzer M, Lauer UM. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. Gynecol Oncol 2013; 130:362-8; PMID:23676551; http://dx.doi.org/10.1016/j.ygyno.2013.05.004
55. Lampe J, Bossow S, Weiland T, Smirnow I, Lehmann R, Neubert W, Bitzer M, Lauer UM. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis. Gene Ther 2013; 20:1033-41; PMID:23719065; http://dx.doi.org/10.1038/gt.2013.28
56. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas. Cancer Gene Ther 2000; 7:732-8; PMID:10830720; http://dx.doi.org/10.1038/sj.cgt.7700160
57. Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13:1011-22; PMID:16799468; http://dx.doi.org/10.1038/sj.cgt.7700969
58. Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther 2013; 14:1016-23; PMID:24025362; http://dx.doi.org/10.4161/cbt.26043
59. Jiang G, Li J, Zeng Z, Xian L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006; 5:435-40; PMID:16575205; http://dx.doi.org/10.4161/cbt.5.4.2542
60. Shen W, Tu JK, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. Oncol Rep 2010; 24:1285-90; PMID:20878122
61. Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009; 28:81; PMID:19527508; http://dx.doi.org/10.1186/1756-9966-28-81
62. Chinnery F, King CA, Elliott T, Bateman AR, James E. Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. Oncoimmunology 2012; 1:874-83; PMID:23162755; http://dx.doi.org/10.4161/onci.20636
63. Woller N, Kühnel F, Kubicka S. Virus infections in tumors pave the way for tumor-directed DC-vaccines. Oncoimmunology 2012; 1:208-10; PMID:22720244; http://dx.doi.org/10.4161/onci.1.2.18099
64. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013; 12:103; PMID:24020520; http://dx.doi.org/10.1186/1476-4598-12-103
65. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013; 20:7-15; PMID:22170342; http://dx.doi.org/10.1038/gt.2011.205
66. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 2013; 21:620-8; PMID:23229093; http://dx.doi.org/10.1038/mt.2012.257
67. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 2014; 22:251-6; PMID:24048442; http://dx.doi.org/10.1038/mt.2013.220
68. Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Immunogenic HSVmediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22:123-31; PMID:24343053; http://dx.doi.org/10.1038/mt.2013.238
69. Workenhe ST, Mossman KL. Rewiring cancer cell death to enhance oncolytic viroimmunotherapy. Oncoimmunology 2013; 2:e27138; PMID:24498567; http://dx.doi.org/10.4161/onci.27138
70. Granot T, Yamanashi Y, Meruelo D. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol Ther 2014; 22:112-22; PMID:24025748; http://dx.doi.org/10.1038/mt.2013.215
71. Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5:185ra63; PMID:23677592; http://dx.doi.org/10.1126/scitranslmed.3005361
72. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21:1212-23; PMID:23546299; http://dx.doi.org/10.1038/mt.2013.51
73. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSFcoding oncolytic adenovirus. Clin Cancer Res 2013; 19:2734-44; PMID:23493351; http://dx.doi.org/10.1158/1078-0432.CCR-12-2546
74. Batenchuk C, Le Boeuf F, Stubbert L, Falls T, Atkins HL, Bell JC, Conrad DP. Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J 2013; 3:e123; PMID:23852158; http://dx.doi.org/10.1038/bcj.2013.23
75. Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther 2014; 22:420-9; PMID:24322333; http://dx.doi.org/10.1038/mt.2013.249
76. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013; 21:887-94; PMID:23295947; http://dx.doi.org/10.1038/mt.2012.265
77. Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology 2013; 2:e26013; PMID:24083086; http://dx.doi.org/10.4161/onci.26013
78. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18:1430-9; PMID:20551919; http://dx.doi.org/10.1038/mt.2010.98
79. Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K, Koshy S, Bramson JL, Wan Y. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009; 17:1814-21; PMID:19603003; http://dx.doi.org/10.1038/mt.2009.154
80. Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
81. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012; 72:1621-31; PMID:22323527; http://dx.doi.org/10.1158/0008-5472.CAN-11-3001
82. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 2009; 15:1317-25; PMID:19228733; http://dx.doi.org/10.1158/1078-0432.CCR-08-1360
83. Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006; 13:1010-20; PMID:16525479; http://dx.doi.org/10.1038/sj.gt.3302759
84. Parviainen S, Ahonen M, Diaconu I, Hirvinen M, Karttunen Å, Vähä-Koskela M, Hemminki A, Cerullo V. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther 2014; 21:195-204; PMID:24305418; http://dx.doi.org/10.1038/gt.2013.73
85. Zamarin D, Vigil A, Kelly K, García-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16:796-804; PMID:19242529; http://dx.doi.org/10.1038/gt.2009.14
86. Takehara Y, Satoh T, Nishizawa A, Saeki K, Nakamura M, Masuzawa M, Kaneda Y, Katayama I, Yokozeki H. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. Clin Immunol 2013; 149:1-10; PMID:23886549; http://dx.doi.org/10.1016/j.clim.2013.05.019
87. Beyer M. Interleukin-2 treatment of tumor patients can expand regulatory T cells. Oncoimmunology 2012; 1:1181-2; PMID:23170272; http://dx.doi.org/10.4161/onci.20639
88. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS, Stiles BM, Shah JP, Singh B, Fong Y. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10:4509-16; PMID:15240543; http://dx.doi.org/10.1158/1078-0432.CCR-04-0081
89. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 2011; 19:1558-68; PMID:21468000; http://dx.doi.org/10.1038/mt.2011.29
90. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 97:2208-13; PMID:10681459; http://dx.doi.org/10.1073/pnas.040557897
91. Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther 2013; 20:17-24; PMID:23138870; http://dx.doi.org/10.1038/cgt.2012.75
92. Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 2013; 15:591-9; PMID:23730207
93. Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 2013; 20:1131-9; PMID:23842593; http://dx.doi.org/10.1038/gt.2013.40
94. Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, et al. Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates. Hum Gene Ther Clin Dev 2014.
95. Malvicini M, Alaniz L, Bayo J, Garcia M, Piccioni F, Fiore E, Atorrasagasti C, Aquino JB, Matar P, Mazzolini G. Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology 2012; 1:1038-47; PMID:23170252; http://dx.doi.org/10.4161/onci.20684
96. Wong HC, Jeng EK, Rhode PR. The IL-15-based superagonist ALT-803 promotes the antigenindependent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2013; 2:e26442; PMID:24404427; http://dx.doi.org/10.4161/onci.26442
97. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012; 19:238-46; PMID:22158521; http://dx.doi.org/10.1038/cgt.2011.81
98. Liu J, Wennier S, Reinhard M, Roy E, MacNeill A, McFadden G. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 2009; 83:5933-8; PMID:19279088; http://dx.doi.org/10.1128/JVI.00204-09
99. van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, Seipelt J, Doerr HW, Cinatl J Jr. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One 2012; 7:e36506; PMID:22563505; http://dx.doi.org/10.1371/journal.pone.0036506
100. Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionallyreplicating oncolytic HSV-1. PLoS One 2013; 8:e81768; PMID:24312353; http://dx.doi.org/10.1371/journal.pone.0081768
101. Vincent M, Quéméner A, Jacques Y. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology 2013; 2:e26441; PMID:24349876; http://dx.doi.org/10.4161/onci.26441
102. Choi IK, Li Y, Oh E, Kim J, Yun CO. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity. PLoS One 2013; 8:e67512; PMID:23844018; http://dx.doi.org/10.1371/journal.pone.0067512
103. Jiang G, Jiang AJ, Cheng Q, Tian H, Li LT, Zheng JN. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. Tumour Biol 2013; 34:1263-71; PMID:23430584; http://dx.doi.org/10.1007/s13277-013-0701-7
104. Lou W, Chen Q, Ma L, Liu J, Yang Z, Shen J, Cui Y, Bian XW, Qian C. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med (Berl) 2013; 91:715-25; PMID:23292172; http://dx.doi.org/10.1007/s00109-012-0985-x
105. He B, Huang X, Liu X, Xu B. Cancer targeting geneviro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice. Mol Biol Rep 2013; 40:5397-405; PMID:23666064; http://dx.doi.org/10.1007/s11033-013-2638-8
106. Fang L, Cheng Q, Bai J, Qi YD, Liu JJ, Li LT, Zheng JN. An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells. Mol Med Rep 2013; 8:1416-24; PMID:24042845
107. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937-47; PMID:21630267; http://dx.doi.org/10.1002/ijc.26216
108. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188:2391-7; PMID:23088985; http://dx.doi.org/10.1016/j.juro.2012.07.097
109. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
110. Thorne SH. The role of GM-CSF in enhancing immunotherapy of cancer. Immunotherapy 2013; 5:817-9; PMID:23902549; http://dx.doi.org/10.2217/imt.13.65
111. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. Granulocyte-macrophage colonystimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24:644-54; PMID:23642239; http://dx.doi.org/10.1089/hum.2012.205
112. Liu H, Yuan SJ, Chen YT, Xie YB, Cui L, Yang WZ, Yang DX, Tian YT. Preclinical evaluation of herpes simplex virus armed with granulocytemacrophage colony-stimulating factor in pancreatic carcinoma. World J Gastroenterol 2013; 19:5138-43; PMID:23964149; http://dx.doi.org/10.3748/wjg.v19.i31.5138
113. Egilmez NK, Harden JL, Rowswell-Turner RB. Chemoimmunotherapy as long-term maintenance therapy for cancer. Oncoimmunology 2012; 1:563-5; PMID:22754788; http://dx.doi.org/10.4161/onci.19369
114. Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S, Berghmans N, Geibig R, Rommelaere J, Van Damme J, et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother 2012; 61:2113-23; PMID:22576056; http://dx.doi.org/10.1007/s00262-012-1279-4
115. Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012; 14:1115-21; PMID:23308044
116. Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology 2013; 2:e23658; PMID:23734319; http://dx.doi.org/10.4161/onci.23658
117. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palù G. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 2005; 12:835-48; PMID:15891772; http://dx.doi.org/10.1038/sj.cgt.7700851
118. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 2010; 70:598-608; PMID:20068158; http://dx.doi.org/10.1158/0008-5472.CAN-09-1510
119. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3:1354-61; PMID:9396605; http://dx.doi.org/10.1038/nm1297-1354
120. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther 2005; 12:147-59; PMID:15372069; http://dx.doi.org/10.1038/sj.gt.3302390
121. Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, Kallajoki MA, Kähäri VM, Hinkkanen AE. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 2006; 66:7185-94; PMID:16849565; http://dx.doi.org/10.1158/0008-5472.CAN-05-2214
122. Cordaro TA, de Visser KE, Tirion FH, Graus YM, Haanen JB, Kioussis D, Kruisbeek AM. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur J Immunol 2000; 30:1297-307; PMID:10820375; http://dx.doi.org/10.1002/(SICI)1521-4141(200005)30:5<1297::AIDIMMU1297> 3.0.CO;2-C
123. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Mol Ther 2004; 9:650-7; PMID:15120325; http://dx.doi.org/10.1016/j.ymthe.2004.01.021
124. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62:1063-8; PMID:11861383
125. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60:4251-5; PMID:10945638
126. Bilbao R, Bustos M, Alzuguren P, Pajares MJ, Drozdzik M, Qian C, Prieto J. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther 2000; 7:1824-32; PMID:11110414; http://dx.doi.org/10.1038/sj.gt.3301312
127. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006; 4:61-70; PMID:16513837; http://dx.doi.org/10.1158/1541-7786.MCR-06-0002
128. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97:3746-54; PMID:11389012; http://dx.doi.org/10.1182/blood.V97.12.3746
129. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62:4656-62; PMID:12183422
130. Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR, Desmond RA, Wang M, Takayama K, Hakkarainen T, et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005; 12:87-94; PMID:15385953; http://dx.doi.org/10.1038/sj.gt.3302387
131. Alain T, Kim M, Johnston RN, Urbanski S, Kossakowska AE, Forsyth PA, Lee PW. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer 2006; 95:1020-7; PMID:17047650; http://dx.doi.org/10.1038/sj.bjc.6603363
132. Kim YT, Ganly I, Brown R, Stuart D. Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines. Cancer Gene Ther 2003; 10:589-90; PMID:12872140; http://dx.doi.org/10.1038/sj.cgt.7700607
133. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID:21527953; http://dx.doi.org/10.1038/nrm3115
134. Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M, Kroemer G. Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 2011; 18:1403-13; PMID:21072053; http://dx.doi.org/10.1038/cdd.2010.145
135. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8:341-8; PMID:11313809; http://dx.doi.org/10.1038/sj.gt.3301389
136. Massari I, Donnini A, Argentati K, Straino S, Mangoni A, Gaetano C, Viticchi C, Capogrossi M, Provinciali M. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats. Exp Gerontol 2002; 37:823-31; PMID:12175482; http://dx.doi.org/10.1016/S0531-5565(02)00011-6
137. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74:4765-75; PMID:10775615; http://dx.doi.org/10.1128/JVI.74.10.4765-4775.2000
138. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7:1095-101; PMID:8773511; http://dx.doi.org/10.1089/hum.1996.7.9-1095
139. Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM, Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003; 8:746-55; PMID:14599807; http://dx.doi.org/10.1016/j.ymthe.2003.07.006
140. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20:825-52; PMID:11861619; http://dx.doi.org/10.1146/annurev.immunol.20.103001.114744
141. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009; 20:975-88; PMID:19469693; http://dx.doi.org/10.1089/hum.2009.028
142. Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol 2012; 2012:805629; PMID:22400027; http://dx.doi.org/10.1155/2012/805629
143. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583-94; PMID:23567086; http://dx.doi.org/10.1016/j.jhep.2013.03.033
144. Chisholm J, Howe K, Taj M, Zambon M. Influenza immunisation in children with solid tumours. Eur J Cancer 2005; 41:2280-7; PMID:16143516; http://dx.doi.org/10.1016/j.ejca.2005.07.006
145. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104:618-28; PMID:15973737; http://dx.doi.org/10.1002/cncr.21203
146. Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer: more than just "common colds". Cancer 2003; 97:2576-87; PMID:12733157; http://dx.doi.org/10.1002/cncr.11353
147. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-98; PMID:11208818
148. Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21:1119-28; PMID:20486770; http://dx.doi.org/10.1089/hum.2010.020
149. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6; PMID:12529469; http://dx.doi.org/10.1056/NEJM200301163480314
150. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.1126/science.1088547
151. Thaci B, Ulasov IV, Ahmed AU, Ferguson SD, Han Y, Lesniak MS. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther 2013; 20:318-27; PMID:22673390; http://dx.doi.org/10.1038/gt.2012.42
152. Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, et al. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer 2013; 132:485-94; PMID:22729516; http://dx.doi.org/10.1002/ijc.27681
153. Wang H, Wei F, Li H, Ji X, Li S, Chen X. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model. Int J Mol Med 2013; 31:377-85; PMID:23229955
154. Li LX, Zhang YL, Zhou L, Ke ML, Chen JM, Fu X, Ye CL, Wu JX, Liu RY, Huang W. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. J Transl Med 2013; 11:257; PMID:24124726; http://dx.doi.org/10.1186/1479-5876-11-257
155. Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73:1265-75; PMID:23393196; http://dx.doi.org/10.1158/0008-5472.CAN-12-2687
156. Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A 2013; 110:E1291-300; PMID:23509246; http://dx.doi.org/10.1073/pnas.1220580110
157. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
158. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91:1071-121; PMID:21742796; http://dx.doi.org/10.1152/physrev.00038.2010
159. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73:2943-8; PMID:23440426; http://dx.doi.org/10.1158/0008-5472.CAN-12-4354
160. Long KB, Beatty GL. Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology 2013; 2:e26860; PMID:24498559; http://dx.doi.org/10.4161/onci.26860
161. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013; 2:e25961; PMID:24083084; http://dx.doi.org/10.4161/onci.25961
162. Chandra D, Gravekamp C. Myeloid-derived suppressor cells: Cellular missiles to target tumors. Oncoimmunology 2013; 2:e26967; PMID:24427545; http://dx.doi.org/10.4161/onci.26967
163. Pan PY, Chen HM, Chen SH. Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology 2013; 2:e25083; PMID:24083075; http://dx.doi.org/10.4161/onci.25083
164. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
165. Muthana M, Rodrigues S, Chen YY, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res 2013; 73:490-5; PMID:23172310; http://dx.doi.org/10.1158/0008-5472.CAN-12-3056
166. Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, et al. Cytotoxic and immunemediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 2013; 132:2327-38; PMID:23114986; http://dx.doi.org/10.1002/ijc.27918
167. Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, Ward S, Divino C, Woo S, Chen SH, et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res 2013; 73:5003-15; PMID:23536556; http://dx.doi.org/10.1158/0008-5472.CAN-12-1597
168. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 2013; 11:20; PMID:23347343; http://dx.doi.org/10.1186/1479-5876-11-20
169. Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol 2013; 59:999-1006; PMID:23867315; http://dx.doi.org/10.1016/j.jhep.2013.07.010
170. Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM, Fielding AK. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014; 123:1327-35; PMID:24345754; http://dx.doi.org/10.1182/blood-2013-09-528851
171. Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer 2013; 132:1592-601; PMID:22949155; http://dx.doi.org/10.1002/ijc.27823
172. Amit M, Gil Z. Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase. Oncoimmunology 2013; 2:e27231; PMID:24498570; http://dx.doi.org/10.4161/onci.27231
173. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.y: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
174. Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 2013; 20:521-8; PMID:22895509; http://dx.doi.org/10.1038/gt.2012.68
175. Zeng WG, Li JJ, Hu P, Lei L, Wang JN, Liu RB. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep 2013; 29:2355-61; PMID:23525624
176. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
177. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ, Dispenzieri A, Russell SJ. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2013; 20:255-61; PMID:22476202; http://dx.doi.org/10.1038/gt.2012.31
178. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026
179. Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2013; 2:e22246; PMID:23482454; http://dx.doi.org/10.4161/onci.22246
180. Jha BK, Dong B, Nguyen CT, Polyakova I, Silverman RH. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol Ther 2013; 21:1749-57; PMID:23732991; http://dx.doi.org/10.1038/mt.2013.112
181. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
182. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10.1182/blood-2007-07-100362
183. Liu RY, Peng JL, Li YQ, Huang BJ, Lin HX, Zhou L, Luo HL, Huang W. Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin. Anat Rec (Hoboken) 2013; 296:1833-41; PMID:24136729
184. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
185. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T, et al. miR-181a and miR-630 regulate cisplatininduced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi.org/10.1158/0008-5472.CAN-09-3112
186. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep.2012.06.017
187. Cody JJ, Markert JM, Hurst DR. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One 2014; 9:e92919; PMID:24651853; http://dx.doi.org/10.1371/journal.pone.0092919
188. Nomura M, Shimbo T, Miyamoto Y, Fukuzawa M, Kaneda Y. 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma. Cancer Sci 2013; 104:238-44; PMID:23134437; http://dx.doi.org/10.1111/cas.12063
189. Carlson LM, De Geer A, Sveinbjørnsson B, Orrego A, Martinsson T, Kogner P, Levitskaya J. The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology 2013; 2:e23618; PMID:23802089; http://dx.doi.org/10.4161/onci.23618
190. Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, et al. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 2013; 4:84-9; PMID:23093804; http://dx.doi.org/10.4161/bioe.22462
191. Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, Nolte I, Frentzen A, Szalay AA. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS One 2012; 7:e47472; PMID:23091626; http://dx.doi.org/10.1371/journal.pone.0047472
192. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012; 7:e37239; PMID:22615950; http://dx.doi.org/10.1371/journal.pone.0037239
193. Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 2012; 10:3; PMID:22216938; http://dx.doi.org/10.1186/1479-5876-10-3
194. Hwang CC, Umeki S, Kubo M, Hayashi T, Shimoda H, Mochizuki M, Maeda K, Baba K, Hiraoka H, Coffey M, et al. Oncolytic reovirus in canine mast cell tumor. PLoS One 2013; 8:e73555; PMID:24073198; http://dx.doi.org/10.1371/journal.pone.0073555
195. Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res 2012; 115:265-318; PMID:23021247; http://dx.doi.org/10.1016/B978-0-12-398342-8.00008-2
196. Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol 2012; 13:1852-7; PMID:21740357; http://dx.doi.org/10.2174/138920112800958760
197. Räty JK, Pikkarainen JT, Wirth T, Ylä-Herttuala S. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol 2008; 1:13-23; PMID:20021420; http://dx.doi.org/10.2174/1874467210801010013
198. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
199. Aranda F, Vacchelli E, Obrist F, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2014; 3:e28344; (Forthcoming)
200. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
201. Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/onci.26494
202. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12:1198-205; PMID:15800658; http://dx.doi.org/10.1038/sj.gt.3302517
203. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58; PMID:12946318; http://dx.doi.org/10.1016/S1525-0016(03)00200-4
204. Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, et al. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013; 130:518-24; PMID:23756180; http://dx.doi.org/10.1016/j.ygyno.2013.06.003
205. Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 2013; (Forthcoming); PMID:24374597
206. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71:5601-5; PMID:21846822; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316
207. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223
208. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
209. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61-9; PMID:21249425; http://dx.doi.org/10.1007/s10555-011-9273-4
210. Honeychurch J, Dive C, Illidge TM. Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncoimmunology 2013; 2:e24501; PMID:23894711; http://dx.doi.org/10.4161/onci.24501
211. Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. Oncoimmunology 2013; 2:e22409; PMID:23482968; http://dx.doi.org/10.4161/onci.22409
212. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; PMID:24404424; http://dx.doi.org/10.4161/onci.26536
213. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/onci.24568
214. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
215. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9:533-42; PMID:18495536; http://dx.doi.org/10.1016/S1470-2045(08)70107-4
216. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477:99-102; PMID:21886163; http://dx.doi.org/10.1038/nature10358
217. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, et al. A mechanistic proof-ofconcept clinical trial with JX-594, a targeted multimechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19:1913-22; PMID:21772252; http://dx.doi.org/10.1038/mt.2011.132
218. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-74; PMID:10845725; http://dx.doi.org/10.1038/sj.gt.3301205
219. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001; 98:6396-401; PMID:11353831; http://dx.doi.org/10.1073/pnas.101136398
220. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17:199-207; PMID:18957964; http://dx.doi.org/10.1038/mt.2008.228
221. Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, et al. A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. Mol Ther 2014; (Forthcoming); PMID:24572293; http://dx.doi.org/10.1038/mt.2014.22
222. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292-303; PMID:12595888; http://dx.doi.org/10.1038/sj.gt.3301885
223. Galluzzi L, Lugli E. Cancer immunotherapy turns viral. Oncoimmunology 2013; 2:e24802; PMID:23734338; http://dx.doi.org/10.4161/onci.24802
224. Pol JG, Marguerie M, Arulanandam R, Bell JC, Lichty BD. Panorama from the oncolytic virotherapy summit. Mol Ther 2013; 21:1814-8; PMID:24081122; http://dx.doi.org/10.1038/mt.2013.207
225. Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther 2009; 9:817-30; PMID:19527106; http://dx.doi.org/10.1517/14712590903002039
226. Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 2013; 31:696-706; PMID:22886613; http://dx.doi.org/10.1007/s10637-012-9865-z
227. Hirvinen M, Heiskanen R, Oksanen M, Pesonen S, Liikanen I, Joensuu T, Kanerva A, Cerullo V, Hemminki A. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med 2013; 11:193; PMID:23965133; http://dx.doi.org/10.1186/1479-5876-11-193
228. Hemminki O, Immonen R, Närväinen J, Kipar A, Paasonen J, Jokivarsi KT, Yli-Ollila H, Soininen P, Partanen K, Joensuu T, et al. In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Int J Cancer 2014; 134:2878-90; PMID:24248808; http://dx.doi.org/10.1002/ijc.28615
229. Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology 2012; 1:1146-55; PMID:23170261; http://dx.doi.org/10.4161/onci.21542
230. Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela A, Oksanen M, Partanen K, Laasonen L, Kairemo K, Joensuu T, et al. [(18) F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 2013; 24:1029-41; PMID:24099555; http://dx.doi.org/10.1089/hum.2013.123
231. Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014; 32:182-90; PMID:24463573; http://dx.doi.org/10.1038/nbt.2806
232. Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology 2013; 2:e24786; PMID:23894723; http://dx.doi.org/10.4161/onci.24786
233. Becker C, Bopp T, Steinbrink K. Interferon α interferes with immunological tolerance. Oncoimmunology 2013; 2:e27528; PMID:24575381; http://dx.doi.org/10.4161/onci.27528
234. Smits EL, Anguille S, Berneman ZN. Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology 2013; 2:e23619; PMID:23734314; http://dx.doi.org/10.4161/onci.23619
235. James BR, Griffith TS. Activation of systemic antitumor immunity via TRAIL-induced apoptosis. Oncoimmunology 2012; 1:1178-80; PMID:23170271; http://dx.doi.org/10.4161/onci.20638
236. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074-83; PMID:23170255; http://dx.doi.org/10.4161/onci.20897
237. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6:226ra32; PMID:24598590; http://dx.doi.org/10.1126/scitranslmed.3008095
238. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
239. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
240. Mavilio D, Lugli E. Inhibiting the inhibitors: Checkpoints blockade in solid tumors. Oncoimmunology 2013; 2:e26535; PMID:24244910; http://dx.doi.org/10.4161/onci.26535
241. Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis 2013; 4:e728; PMID:23868061; http://dx.doi.org/10.1038/cddis.2013.259
242. Donnelly O, Ilett E, Kottke T, Thompson J, Vile R, Melcher A. Cytokine-enhanced intravenous oncolytic virotherapy. Lancet 2014; 383:S42; (Forthcoming); http://dx.doi.org/10.1016/S0140-6736(14)60305-6
243. Bauzon M, Hermiston TW. Oncolytic viruses: the power of directed evolution. Adv Virol 2012; 2012:586389; PMID:22312363; http://dx.doi.org/10.1155/2012/586389
244. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008; 3:e2409; PMID:18560559; http://dx.doi.org/10.1371/journal.pone.0002409
245. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther 2012; 23:295-301; PMID:22235810; http://dx.doi.org/10.1089/hum.2011.128
246. Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J, Galanis E. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther 2012; 23:419-27; PMID:22185260; http://dx.doi.org/10.1089/hum.2011.158
247. Penheiter AR, Wegman TR, Classic KL, Dingli D, Bender CE, Russell SJ, Carlson SK. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol 2010; 195:341-9; PMID:20651188; http://dx.doi.org/10.2214/AJR.09.3672
248. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010; 18:1155-64; PMID:20234340; http://dx.doi.org/10.1038/mt.2010.43
249. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18:1275-83; PMID:20442708; http://dx.doi.org/10.1038/mt.2010.79
250. Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibañez CE, Kasahara N, Gunzburg W, et al. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther 2013; 20:544-51; PMID:23969884; http://dx.doi.org/10.1038/cgt.2013.51
251. Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012; 20:1689-98; PMID:22547150; http://dx.doi.org/10.1038/mt.2012.83
252. Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, Lin AH, Valenta DT, Perez OD, Ibañez CE, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2012; 14:145-59; PMID:22070930; http://dx.doi.org/10.1093/neuonc/nor199
253. Skelding KA, Barry RD, Shafren DR. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs 2012; 30:568-81; PMID:21170760; http://dx.doi.org/10.1007/s10637-010-9614-0
254. Skelding KA, Barry RD, Shafren DR. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat 2009; 113:21-30; PMID:18256929; http://dx.doi.org/10.1007/s10549-008-9899-2
255. Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005; 26:1471-6; PMID:15870858
256. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004; 10:53-60; PMID:14734451; http://dx.doi.org/10.1158/1078-0432.CCR-0690-3
257. Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. OncoImmunology 2013; 2:e26084; http://dx.doi.org/10.4161/onci.26084
258. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12:305-13; PMID:16397056; http://dx.doi.org/10.1158/1078-0432.CCR-05-1059
259. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
260. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDAapproved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931
261. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007; 67:8255-63; PMID:17804740; http://dx.doi.org/10.1158/0008-5472.CAN-06-4675
262. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15:1607-15; PMID:17579575; http://dx.doi.org/10.1038/sj.mt.6300239
263. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007; 14:756-61; PMID:17557108; http://dx.doi.org/10.1038/sj.cgt.7701067
264. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 2008; 16:487-93; PMID:18253154; http://dx.doi.org/10.1038/sj.mt.6300400
265. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99:1410-4; PMID:17848677; http://dx.doi.org/10.1093/jnci/djm102
266. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95:652-60; PMID:12734316; http://dx.doi.org/10.1093/jnci/95.9.652
267. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357:525-6; PMID:11229673; http://dx.doi.org/10.1016/S0140-6736(00)04048-4
268. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM, Molnar-Kimber KL. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5:1523-37; PMID:10389942
269. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57:466-71; PMID:9012475
270. Randazzo BP, Kucharczuk JC, Litzky LA, Kaiser LR, Brown SM, MacLean A, Albelda SM, Fraser NW. Herpes simplex 1716--an ICP 34.5 mutant--is severely replication restricted in human skin xenografts in vivo. Virology 1996; 223:392-5; PMID:8806577; http://dx.doi.org/10.1006/viro.1996.0493
271. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 2013; 105:1059-65; PMID:23739064; http://dx.doi.org/10.1093/jnci/djt130
272. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007; 99:1623-33; PMID:17971529; http://dx.doi.org/10.1093/jnci/djm198
273. Sieben M, Schäfer P, Dinsart C, Galle PR, Moehler M. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int J Cancer 2013; 132:2548-56; PMID:23151948; http://dx.doi.org/10.1002/ijc.27938
274. Guillerme JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013; 19:1147-58; PMID:23339127; http://dx.doi.org/10.1158/1078-0432.CCR-12-2733
275. Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012; 20:2076-86; PMID:22828500; http://dx.doi.org/10.1038/mt.2012.137
276. Xia M, Gonzalez P, Li C, Meng G, Jiang A, Wang H, Gao Q, Debatin KM, Beltinger C, Wei J. Mitophagy Enhances Oncolytic Measles Virus Replication by Mitigating DDX58/RIG-I-Like Receptor Signaling. J Virol 2014; 88:5152-64; PMID:24574393; http://dx.doi.org/10.1128/JVI.03851-13
277. Kaneda Y. The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis. Oncoimmunology 2013; 2:e23566; PMID:23734313; http://dx.doi.org/10.4161/onci.23566
278. Berchtold S, Lampe J, Weiland T, Smirnow I, Schleicher S, Handgretinger R, Kopp HG, Reiser J, Stubenrauch F, Mayer N, et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J Virol 2013; 87:3484-501; PMID:23302892; http://dx.doi.org/10.1128/JVI.02106-12
279. Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012; 18:6271-83; PMID:23014529; http://dx.doi.org/10.1158/1078-0432.CCR-12-1595
280. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi.org/10.1038/nrm3479
281. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
282. Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther 2013; 21:348-57; PMID:23011032; http://dx.doi.org/10.1038/mt.2012.204
283. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
284. Hasegawa N, Abei M, Yokoyama KK, Fukuda K, Seo E, Kawashima R, Nakano Y, Yamada T, Nakade K, Hamada H, et al. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer 2013; 133:1479-88; PMID:23444104; http://dx.doi.org/10.1002/ijc.28132
285. Ziccheddu G, Proietti E, Moschella F. The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy. Oncoimmunology 2013; 2:e25789; PMID:24244905; http://dx.doi.org/10.4161/onci.25789
286. Kottke T, Chester J, Ilett E, Thompson J, Diaz R, Coffey M, Selby P, Nuovo G, Pulido J, Mukhopadhyay D, et al. Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther 2011; 19:1802-12; PMID:21792179; http://dx.doi.org/10.1038/mt.2011.147
287. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; PMID:23894726; http://dx.doi.org/10.4161/onci.25396